Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health executive Steven H. Nelson, EVP and President of Aetna, reported routine equity compensation and related tax withholding. He received a stock option grant for 143,712 shares of common stock at $71.82 per share, exercisable in three equal annual installments beginning March 31, 2027 and expiring in 2036. He was also awarded 22,277 restricted shares, with restrictions lapsing in three equal installments starting March 31, 2027. To cover withholding taxes on vesting and settlement of restricted stock units, 2,432 common shares were surrendered, leaving him with 2,900 common shares directly held and 43,606 restricted shares reported after the award.
CVS Health EVP and Chief Experience & Technology Officer Tilak Mandadi reported routine equity compensation moves. He received a grant of 143,712 stock options for Common Stock at an exercise price of $71.82 per share, exercisable in three equal annual installments beginning on 3/31/2027, and expiring on 3/31/2036.
Mandadi was also awarded 22,277 restricted stock units of Common Stock at $71.82 per share under CVS Health’s 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments starting on 3/31/2027. In a related tax-withholding event, 3,634 shares of Common Stock were surrendered at $72.49 per share to cover taxes due upon the vesting and settlement of restricted stock units. After these transactions, he directly holds 79,684 shares of CVS Health Common Stock.
CVS Health executive Samrat S. Khichi, EVP, CPO and General Counsel, received equity compensation and had shares withheld for taxes. On March 31, 2026, he was granted 80,838 stock options with an exercise price of $71.82 per share, exercisable in three equal annual installments starting March 31, 2027 until expiration on March 31, 2036. He also received 12,531 restricted stock units under the 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments beginning March 31, 2027. On April 1, 2026, 3,541 shares of common stock at $72.49 per share were surrendered to pay withholding taxes upon RSU vesting, leaving him with 33,421 common shares held directly.
CVS Health President, CEO and Chair J. David Joyner reported routine equity compensation activity. He received 86,326 shares of Common Stock in the form of restricted stock units under the company’s 2017 Incentive Compensation Plan, valued at $71.82 per share. These RSUs vest in three equal installments beginning on March 31, 2027.
In a separate transaction tied to RSU vesting and settlement, Joyner surrendered 8,029 shares of common stock at $72.49 per share to cover withholding tax obligations. After this tax-withholding disposition, he directly holds 70,349 shares of CVS common stock and 160,860 RSUs. These are non‑open‑market, compensation-related transactions rather than discretionary stock purchases or sales.
CVS Health reported that EVP and Chief Medical Officer Amy Compton-Phillips received equity compensation awards. She was granted stock options for 35,928 shares of common stock at an exercise price of $71.82 per share, expiring on March 31, 2036. These options become exercisable in three equal annual installments starting March 31, 2027. She also received 5,569 restricted stock units (RSUs) under the 2017 Incentive Compensation Plan, which vest in three equal installments beginning March 31, 2027. Following these grants, she directly holds 58,660 shares of CVS common stock. These awards are grants, not open-market purchases or sales.
CVS Health senior vice president and chief accounting officer James David Clark reported routine equity compensation changes. On March 31, 2026, he received 11,138 shares of restricted common stock and a stock option for 11,976 shares at $71.82 per share, both vesting in three equal annual installments starting March 31, 2027. On April 1, 2026, 3,262 shares of common stock, valued at $72.49 per share, were surrendered to cover withholding taxes due at vesting, leaving him with 15,457 common shares held directly.
CVS HEALTH Corp executive Heidi B. Capozzi reported routine equity compensation and related tax withholding. She received stock options for 64,670 shares of common stock at $71.82 per share, exercisable in three equal annual installments starting March 31, 2027 and expiring on March 31, 2036. She was also granted 10,025 restricted stock units at $71.82 per share under the 2017 Incentive Compensation Plan, with restrictions lapsing in three equal installments beginning March 31, 2027. In a separate transaction, 1,334 common shares at $72.49 were surrendered to cover withholding taxes on RSU vesting, leaving her with 13,023 directly held common shares.
CVS Health Corp — The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A describing an internal realignment and reporting 0 shares and 0% beneficial ownership of CVS common stock. The filing notes the realignment took place January 12, 2026 and the amendment is signed on 03/26/2026.
Gallina John E reported acquisition or exercise transactions in this Form 4 filing.
CVS Health Corp director John E. Gallina reported receiving a grant of common stock as part of his board compensation. He was awarded 582 shares of CVS common stock on March 19, 2026 at a reference price of $71.86 per share, issued as payment of a pro rata semi-annual retainer under the 2017 Incentive Compensation Plan. Following this grant, he directly owns 582 CVS shares, reflecting a compensation-related equity award rather than an open-market purchase.
CVS Health Corp filed an initial ownership report for John E. Gallina, who is identified as a director of the company. This Form 3 does not list any stock transactions or holdings details in the provided data, serving mainly to register him as an insider for future reporting.